|
|
Blood, 1 September 2004, Vol. 104, No. 5, pp. 1559-1564.
Prepublished online as a Blood First Edition Paper on May 11, 2004; DOI 10.1182/blood-2004-03-0854.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
Stephanie J. Lee,
David Zahrieh,
Edward Agura,
Margaret L. MacMillan,
Richard T. Maziarz,
Philip L. McCarthy, Jr,
Vincent T. Ho,
Corey Cutler,
Edwin P. Alyea,
Joseph H. Antin, and
Robert J. Soiffer
From the Departments of Adult Oncology and Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Baylor University Medical Center, Dallas, TX; University of Minnesota, Minneapolis, MN; Oregon Health and Science University, Portland, OR; and Roswell Park Cancer Institute, Buffalo, NY.
The standard initial therapy for acute graft-versus-host disease (GVHD) is corticosteroids. Daclizumab is a humanized monoclonal antibody against the interleukin 2 (IL-2) receptor expressed on activated T lymphocytes. Because of daclizumab's favorable toxicity profile and response rate in steroid-resistant GVHD, a multicenter, double-blinded, randomized study of corticosteroids with or without daclizumab for initial treatment of acute GVHD was conducted. A total of 102 evaluable subjects of the targeted 166 were enrolled at 5 participating sites. Methylprednisolone at a dose of 2 mg/kg or daily equivalent was given in conjunction with daclizumab 1 mg/kg or placebo on study days 1, 4, 8, and weekly as long as clinically indicated. The groups were balanced for clinical characteristics. GVHD response rates by study day 42 were similar (53% vs 51%; P = .85). The study was halted after a planned interim analysis showed a significantly worse 100-day survival in the group receiving corticosteroids plus daclizumab (77% vs 94%; P = .02). Overall survival at 1 year was also inferior in the combination arm (29% vs 60%; P = .002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
GVHD therapy: the best-laid schemes...
- Krishna V. Komanduri and Richard E. Champlin
Blood 2004 104: 1240-1241.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. Gratwohl
At last, an "ointment" for gastrointestinal GVHD?
Blood,
May 15, 2007;
109(10):
4117 - 4117.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Van Lint, G. Milone, S. Leotta, C. Uderzo, R. Scime, S. Dallorso, A. Locasciulli, S. Guidi, N. Mordini, S. Sica, et al.
Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin
Blood,
May 15, 2006;
107(10):
4177 - 4181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Knoechel, J. Lohr, E. Kahn, J. A. Bluestone, and A. K. Abbas
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen
J. Exp. Med.,
November 21, 2005;
202(10):
1375 - 1386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kober, J. Bohlius, S. Trelle, and A. Engert
Second Biannual Report of the Cochrane Haematological Malignancies Group
J Natl Cancer Inst,
April 6, 2005;
97(7):
E1 - E.
[Full Text]
|
|
|
|
|
|
|
T. Iwasaki
Recent Advances in the Treatment of Graft-Versus-Host Disease
Clin. Med. Res.,
November 1, 2004;
2(4):
243 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
